Arthritis News and Research

Latest Arthritis News and Research

Report: Obesity rates will continue to grow, causing increases in health care costs, disease incidence

The Robert Wood Johnson Foundation and Trust for America's Health concluded that, based on current trends, most Americans could be obese by 2030.

20 Sep 2012

Hip implants are more likely to fail in obese people due to thigh size

University of Iowa researchers have determined that thigh size in obese people is a reason their hip implants are more likely to fail.

20 Sep 2012

Positive data from Nektar’s NKTR-192 Phase 1a study on acute pain

Nektar Therapeutics announced today that positive data from the first single-ascending dose Phase 1a clinical study of NKTR-192, the company's novel short-acting mu-opioid analgesic candidate, demonstrate that the drug candidate achieved its target pharmacokinetic profile.

19 Sep 2012

Friendly bacteria: do we really need to eat probiotic yogurts?

According to the World Health Organization (WHO) probiotics are “live microorganisms which when administered in adequate amounts confer a health benefit on the host”.

19 Sep 2012

Pfizer announces that 14 abstracts for tofacitinib to be presented at ACR/ARHP annual meeting

Pfizer Inc. announced today that 14 abstracts for tofacitinib, an investigational oral Janus kinase (JAK) inhibitor for the treatment of adults with moderate-to-severe active rheumatoid arthritis (RA), will be presented at the American College of Rheumatology (ACR) / Association of Rheumatology Health Professionals (ARHP) 2012 Annual Meeting, which is being held November 9-14 in Washington, D.C.

18 Sep 2012

Orthopedists should suspect necrotizing fasciitis in patients with out of proportion pain

Dr. Russell Russo, an Orthopedic Surgeon at LSU Health Sciences Center New Orleans, and other researchers stress that orthopedists should have a high index of suspicion for necrotizing fasciitis, or flesh-eating bacterial infection, in every patient with pain or other symptoms that are out of proportion to the initial diagnosis. Their recommendations are published in the September 2012 issue of Orthopedics Today.

17 Sep 2012

Scientists solve co-crystal structure of human antibody that can neutralize influenza viruses

Scientists from The Scripps Research Institute and Sea Lane Biotechnologies have solved the co-crystal structure of a human antibody that can neutralize influenza viruses in a unique way.

17 Sep 2012

Genzyme receives FDA approval for AUBAGIO to treat relapsing forms of MS

Genzyme, a Sanofi company, announced today that the U.S. Food and Drug Administration (FDA) has approved AUBAGIO (teriflunomide) as a new once-daily, oral treatment indicated for patients with relapsing forms of multiple sclerosis (MS).

13 Sep 2012

Annual economic cost of chronic pain is as high as $635 billion: Study

Health economists from Johns Hopkins University writing in The Journal of Pain (www.jpain.org) reported the annual cost of chronic pain is as high as $635 billion a year, which is more than the yearly costs for cancer, heart disease and diabetes.

12 Sep 2012

APS conference to explore potential mechanisms behind health benefits of exercise

The effects of physical inactivity are, literally, hazardous to your health. Although the detrimental effects of being inactive are generally thought to be associated with childhood obesity and Type 2 diabetes, they have a significant impact on other illnesses. Physical inactivity contributed at least 25 percent to the prevalence of hip fractures, osteoporosis, coronary heart disease, and colon cancer according to recent data released by the U.S. Department of Health and Human Services.

12 Sep 2012

Scripps scientists discover new antibody-discovery technique

Scientists at The Scripps Research Institute have found a new technique that should greatly speed the discovery of medically and scientifically useful antibodies, immune system proteins that detect and destroy invaders such as bacteria and viruses. New methods to discover antibodies are important because antibodies make up the fastest growing sector of human therapeutics; it is estimated that by 2014 the top-three selling drugs worldwide will be antibodies.

12 Sep 2012

BRI scientists receive two major grant awards for research into autoimmunity prevention

Benaroya Research Institute at Virginia Mason (BRI) recently received two major grant awards to explore how to regulate the immune system, as part of a nationwide collaborative program to prevent autoimmune diseases.

11 Sep 2012

Rhode Island receives NIH grant to study cartilage and joint health

Rhode Island Hospital's Center of Biomedical Research Excellence (COBRE) in Skeletal Health and Repair has been awarded a $10.8 million grant from the National Institutes of Health (NIH), one of the largest grants in Rhode Island Hospital history. This grant, to be paid over five years, will fund studies of cartilage and joint health.

11 Sep 2012

Combining two drugs may offer new and potent punch against cancer and other diseases

A new study by researchers at Weill Cornell Medical College shows combining two already-FDA approved drugs may offer a new and potent punch against diseases in which blood vessel growth is abnormal -- such as cancer, diabetic retinopathy, macular degeneration and rheumatoid arthritis.

11 Sep 2012

Oxyphenbutazone can kill drug resistant TB

An off-patent anti-inflammatory drug that costs around two cents for a daily dose in developing countries has been found by researchers at Weill Cornell Medical College to kill both replicating and non-replicating drug resistant tuberculosis in the laboratory -- a feat few currently approved TB drugs can do, and resistance to those is spreading.

11 Sep 2012

Plasma biomarker predicts rheumatoid arthritis onset

Healthy individuals with high levels of immunoglobulin G rheumatoid factor have a significantly increased risk for developing rheumatoid arthritis, suggests population-based research published in the BMJ.

10 Sep 2012

'No malignancy risk' with biologic response modifiers

Rheumatoid arthritis patients treated with biologic response modifiers for at least 6 months do not have a greater risk for malignancy than those given other disease-modifying drugs or placebo, conclude US and Spanish researchers.

10 Sep 2012

Top line results from Zalicus Synavive Phase 2b study in rheumatoid arthritis

Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, today announced top line results from its randomized, double-blind, placebo-controlled, Phase 2b clinical trial of Synavive in rheumatoid arthritis.

10 Sep 2012

CPF to kick off 'Pulmonary Fibrosis Awareness Month'

Each year around the world, as many as 48,000 people are diagnosed with pulmonary fibrosis and 40,000 people die – the same number of people who are lost to breast cancer annually. Pulmonary fibrosis is a devastating disease that robs people of their ability to breathe. To help raise awareness about this unknown deadly disease, the Coalition for Pulmonary Fibrosis (CPF) is kicking off "Pulmonary Fibrosis Awareness Month" this September.

10 Sep 2012

Hebrew University researcher develops anti-inflammatory and anti-allergic family of drugs

A synthetic, anti-inflammatory and anti-allergic family of drugs to combat a variety of illnesses while avoiding detrimental side effects has been developed by a Hebrew University of Jerusalem researcher.

7 Sep 2012

Arthritis News and Research

Latest Arthritis News and Research

Report: Obesity rates will continue to grow, causing increases in health care costs, disease incidence

Hip implants are more likely to fail in obese people due to thigh size

Positive data from Nektar’s NKTR-192 Phase 1a study on acute pain

Friendly bacteria: do we really need to eat probiotic yogurts?

Pfizer announces that 14 abstracts for tofacitinib to be presented at ACR/ARHP annual meeting

Orthopedists should suspect necrotizing fasciitis in patients with out of proportion pain

Scientists solve co-crystal structure of human antibody that can neutralize influenza viruses

Genzyme receives FDA approval for AUBAGIO to treat relapsing forms of MS

Annual economic cost of chronic pain is as high as $635 billion: Study

APS conference to explore potential mechanisms behind health benefits of exercise

Scripps scientists discover new antibody-discovery technique

BRI scientists receive two major grant awards for research into autoimmunity prevention

Rhode Island receives NIH grant to study cartilage and joint health

Combining two drugs may offer new and potent punch against cancer and other diseases

Oxyphenbutazone can kill drug resistant TB

Plasma biomarker predicts rheumatoid arthritis onset

'No malignancy risk' with biologic response modifiers

Top line results from Zalicus Synavive Phase 2b study in rheumatoid arthritis

CPF to kick off 'Pulmonary Fibrosis Awareness Month'

Hebrew University researcher develops anti-inflammatory and anti-allergic family of drugs

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Arthritis News and Research

Latest Arthritis News and Research

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in